Complete Metabolic Response Assessed by FDG PET/CT to FOLFIRI-Aflibercept in Second-Line Treatment of Metastatic Colorectal Cancer

被引：2
|
作者：
Amrane, Karim [1 ]
Ollivier, Luc [2 ]
Salaun, Pierre-Yves [3 ,4 ]
Metges, Jean-Philippe [1 ]
Abgral, Ronan [3 ,4 ]
机构：
[1] Univ Hosp Brest, Dept Oncol, 2 Ave Foch, F-29609 Brest, France
[2] Univ Hosp Brest, Dept Radiotherapy, Brest, France
[3] Univ Hosp Brest, Dept Nucl Med, Brest, France
[4] Bretagne Loire Univ, EA GETBO 3878, IFR 148, Brest, France
来源：
CLINICAL NUCLEAR MEDICINE | 2019年 / 44卷 / 07期
关键词：
mCRC; FOLFIRI-aflibercept; FDG PET; CT; BEVACIZUMAB; OXALIPLATIN; PATIENT; FOLFOX;
D O I：
10.1097/RLU.0000000000002611
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
FOLFIRI-aflibercept chemotherapy is indicated in second-line treatment of metastatic colorectal cancer (mCRC) after progression under FOLFOX (+/- bevacizumab). Nevertheless, its proven therapeutic efficacy in clinical trials was based on partial responses. And to date, only 2 cases of complete response assessed by CT were reported in literature. We report a complete metabolic response assessed by FDG PET/CT in a 50-year-old woman with mCRC treated by FOLFIRI-aflibercept. This also confirms that FDG PET/CT is emerging as a useful approach for therapeutic assessment of targeted drugs in mCRC.
引用
收藏
页码：578 / 579
页数：2
相关论文
共 50 条
  • [41] Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer
    T Macarulla
    A Cervantes
    J Tabernero
    S Roselló
    E Van Cutsem
    S Tejpar
    H Prenen
    E Martinelli
    T Troiani
    B Laffranchi
    V Jego
    O von Richter
    F Ciardiello
    British Journal of Cancer, 2015, 112 : 1874 - 1881
  • [42] Comparison of Quantitative Methods on FDG PET/CT for Treatment Response Evaluation of Metastatic Colorectal Cancer
    Bang J.-I.
    Lim Y.
    Paeng J.C.
    Han S.-W.
    Park S.
    Lee J.M.
    Kim H.J.
    Cheon G.J.
    Lee D.S.
    Chung J.-K.
    Kim T.-Y.
    Kang K.W.
    Nuclear Medicine and Molecular Imaging, 2017, 51 (2) : 147 - 153
  • [43] Metastatic colorectal cancer:: First- and second-line treatment in 2005
    Rougier, P
    Lepère, C
    SEMINARS IN ONCOLOGY, 2005, 32 (06) : S15 - S20
  • [44] Raltitrexed plus oxaliplatin in the second-line treatment of metastatic colorectal cancer
    Vyzula, R
    Kocáková, I
    Demlová, R
    Kiss, I
    Dusek, L
    Jarkovsky, J
    NEOPLASMA, 2006, 53 (02) : 119 - 127
  • [45] FOLFIRI plus bevacizumab versus FOLFIRI plus ramucirumab as second-line chemotherapy for metastatic colorectal cancer in the real-world
    Shimura, T.
    Kitagawa, M.
    Sugimura, N.
    Fukusada, S.
    Tanaka, M.
    Kataoka, H.
    ANNALS OF ONCOLOGY, 2024, 35 : S1439 - S1439
  • [46] Experience with Aflibercept as a second line chemotherapy in metastatic colorectal cancer
    Gonzalez-Flores, E.
    Gonzalez-Astorga, B.
    Urena M, T. Delgado
    Conde, V.
    Sanchez-Toro, C.
    Legeren Alvarez, M.
    Villaescusa, A.
    Galvez Montosa, F.
    Garcia-Garcia, J.
    ANNALS OF ONCOLOGY, 2016, 27 : 41 - 42
  • [47] Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
    Peeters, Marc
    Price, Timothy Jay
    Cervantes, Andres
    Sobrero, Alberto F.
    Ducreux, Michel
    Hotko, Yevhen
    Andre, Thierry
    Chan, Emily
    Lordick, Florian
    Punt, Cornelis J. A.
    Strickland, Andrew H.
    Wilson, Gregory
    Ciuleanu, Tudor-Eliade
    Roman, Laslo
    Van Cutsem, Eric
    Tzekova, Valentina
    Collins, Simon
    Oliner, Kelly S.
    Rong, Alan
    Gansert, Jennifer
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (31) : 4706 - 4713
  • [48] Chemotherapy Response Evaluation in Metastatic Colorectal Cancer with FDG PET/CT and CT Scans
    Monteil, J.
    Mahmoudi, N.
    Leobon, S.
    Roudaut, P. Y.
    El Badaoui, A.
    Verbeke, S.
    Venat-Bouvet, L.
    Martin, J.
    Le Brun-Ly, V.
    Lavau-Denes, S.
    Maubon, A.
    Bouillet, P.
    Pouquet, M.
    Vandroux, J. C.
    Tubiana-Mathieu, N.
    ANTICANCER RESEARCH, 2009, 29 (07) : 2563 - 2568
  • [49] Panitumumab with FOLFIRI versus FOLFIRI alone: results from a randomised phase III study of second-line treatment of patients with metastatic colorectal cancer (mCRC)
    Lordick, F.
    Peeters, M.
    Price, T.
    Hotko, Y.
    Cervantes, A.
    Ducreux, M.
    Andre, T.
    Chan, E.
    Rong, A.
    Gansert, J.
    ONKOLOGIE, 2010, 33 : 3 - 3
  • [50] Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC)
    Peeters, M.
    Price, T.
    Hotko, Y.
    Cervantes, A.
    Ducreux, M.
    Andre, T.
    Chan, E.
    Lordick, F.
    Rong, A.
    Gansert, J.
    EJC SUPPLEMENTS, 2009, 7 (03): : 10 - 10
12345